Clinical Trials Logo

Type 2 Diabetes With Nephropathy clinical trials

View clinical trials related to Type 2 Diabetes With Nephropathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT00949351 Not yet recruiting - Clinical trials for Type 2 Diabetes With Nephropathy

Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy

Start date: September 2009
Phase: Phase 4
Study type: Interventional

Activation of renin-angiotensin plays a crucial role diabetic nephropathy. Angiotensin converting enzyme inhibitor (ACEI) and Angiotensin I receptor blocker (ARB) has been shown renoprotection whether it was used alone or in combination. Aliskiren is a direct renin inhibitor (DRI) that has shown renal benefits and safety when combined with ARB. However, to date, the safety of add on aliskiren to the combination treatment of ACEI and ARB in diabetic nephropathy patients remains to elucidate.